This new urine‑based biomarker panel is specialized for the early, non‑invasive detection and monitoring of obstructive uropathy (OU), a condition that results from anatomical or functional urinary tract obstruction due to congenital causes. Despite the clinical importance of OU, there are currently no validated non-invasive biomarkers that can successfully detect early parenchymal injury, predict disease progression, or guide therapeutic intervention in obstructive nephropathy. These non-invasive biomarkers combine the urinary proteomics with single-cell transcriptomics from the urinary tract and kidney, allowing the identification and tracing of novel biomarkers to their cellular origins and the mapping of specific sites, leading to interventions to stabilize kidney and bladder function and prevent further deterioration and promote recovery.